| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 24 | 2023 | 829 | 3.120 |
Why?
|
| Lipoprotein(a) | 9 | 2022 | 114 | 2.060 |
Why?
|
| Lipoproteins | 9 | 2022 | 177 | 1.970 |
Why?
|
| Cholesterol, LDL | 13 | 2022 | 557 | 1.860 |
Why?
|
| Cardiovascular Diseases | 18 | 2023 | 1861 | 1.770 |
Why?
|
| Coronary Disease | 14 | 2023 | 638 | 1.770 |
Why?
|
| Triglycerides | 10 | 2022 | 562 | 1.710 |
Why?
|
| Stroke | 11 | 2023 | 958 | 1.060 |
Why?
|
| Biomarkers | 37 | 2024 | 2942 | 0.980 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 8 | 2019 | 87 | 0.960 |
Why?
|
| Cholesterol | 7 | 2018 | 525 | 0.950 |
Why?
|
| Brain Ischemia | 4 | 2023 | 251 | 0.920 |
Why?
|
| Troponin T | 14 | 2024 | 245 | 0.900 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 850 | 0.900 |
Why?
|
| Lipoproteins, LDL | 4 | 2019 | 116 | 0.810 |
Why?
|
| Prospective Studies | 28 | 2024 | 6028 | 0.740 |
Why?
|
| Risk Factors | 39 | 2023 | 10010 | 0.730 |
Why?
|
| Prediabetic State | 2 | 2018 | 57 | 0.710 |
Why?
|
| Apolipoprotein C-III | 3 | 2022 | 36 | 0.710 |
Why?
|
| Heart Failure | 11 | 2023 | 2125 | 0.670 |
Why?
|
| C-Reactive Protein | 11 | 2024 | 406 | 0.670 |
Why?
|
| Inflammation | 7 | 2021 | 1402 | 0.650 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 177 | 0.640 |
Why?
|
| Middle Aged | 54 | 2024 | 25966 | 0.620 |
Why?
|
| Apolipoproteins E | 2 | 2018 | 190 | 0.610 |
Why?
|
| Aged | 36 | 2024 | 19069 | 0.540 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2023 | 277 | 0.530 |
Why?
|
| Hypertension | 2 | 2022 | 1284 | 0.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2019 | 715 | 0.500 |
Why?
|
| Carotid Artery Diseases | 3 | 2014 | 147 | 0.500 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 54 | 0.500 |
Why?
|
| Risk Assessment | 15 | 2021 | 3329 | 0.490 |
Why?
|
| Metabolic Syndrome | 7 | 2016 | 329 | 0.470 |
Why?
|
| Lipoproteins, HDL | 2 | 2014 | 96 | 0.460 |
Why?
|
| Apolipoproteins B | 4 | 2019 | 131 | 0.410 |
Why?
|
| Female | 58 | 2024 | 65442 | 0.410 |
Why?
|
| Troponin I | 3 | 2024 | 98 | 0.400 |
Why?
|
| Male | 59 | 2024 | 60038 | 0.400 |
Why?
|
| Humans | 73 | 2024 | 123152 | 0.390 |
Why?
|
| Peptide Fragments | 7 | 2023 | 748 | 0.390 |
Why?
|
| Phospholipases A | 3 | 2005 | 39 | 0.360 |
Why?
|
| Population Surveillance | 2 | 2021 | 383 | 0.360 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 1305 | 0.360 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 133 | 0.350 |
Why?
|
| Apolipoproteins | 3 | 2012 | 68 | 0.350 |
Why?
|
| Spouse Abuse | 1 | 2010 | 16 | 0.350 |
Why?
|
| Incidence | 15 | 2021 | 3049 | 0.350 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2010 | 169 | 0.350 |
Why?
|
| Atrial Fibrillation | 3 | 2024 | 623 | 0.340 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 64 | 0.340 |
Why?
|
| Models, Psychological | 1 | 2010 | 139 | 0.330 |
Why?
|
| Blood Pressure | 6 | 2024 | 1315 | 0.330 |
Why?
|
| Carotid Arteries | 1 | 2010 | 151 | 0.320 |
Why?
|
| Chemokine CCL2 | 4 | 2018 | 114 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2014 | 1225 | 0.300 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 202 | 0.290 |
Why?
|
| United States | 20 | 2021 | 10629 | 0.280 |
Why?
|
| Monocytes | 3 | 2019 | 346 | 0.280 |
Why?
|
| Models, Biological | 2 | 2010 | 1442 | 0.280 |
Why?
|
| Coronary Artery Disease | 4 | 2014 | 745 | 0.270 |
Why?
|
| Obesity | 6 | 2016 | 2226 | 0.260 |
Why?
|
| Cholesterol, HDL | 6 | 2014 | 348 | 0.260 |
Why?
|
| Postprandial Period | 2 | 2016 | 77 | 0.260 |
Why?
|
| Hospitalization | 7 | 2019 | 1733 | 0.250 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 89 | 0.240 |
Why?
|
| Albuminuria | 2 | 2022 | 91 | 0.230 |
Why?
|
| Dioxygenases | 1 | 2024 | 46 | 0.230 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 2112 | 0.220 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 998 | 0.220 |
Why?
|
| Lipids | 5 | 2014 | 514 | 0.220 |
Why?
|
| Prognosis | 9 | 2023 | 4505 | 0.220 |
Why?
|
| Sirolimus | 2 | 2002 | 220 | 0.220 |
Why?
|
| Vascular Stiffness | 2 | 2021 | 75 | 0.210 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2022 | 12 | 0.200 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 6373 | 0.200 |
Why?
|
| Galectin 3 | 1 | 2021 | 31 | 0.190 |
Why?
|
| Peripheral Arterial Disease | 2 | 2016 | 269 | 0.180 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 643 | 0.180 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 17 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 550 | 0.180 |
Why?
|
| Cohort Studies | 11 | 2018 | 4704 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 95 | 0.180 |
Why?
|
| Diet, Western | 1 | 2019 | 17 | 0.170 |
Why?
|
| Blood Glucose | 4 | 2018 | 1114 | 0.170 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 34 | 0.170 |
Why?
|
| Linear Models | 4 | 2017 | 670 | 0.170 |
Why?
|
| Case-Control Studies | 6 | 2018 | 3251 | 0.170 |
Why?
|
| Kidney Transplantation | 2 | 2002 | 628 | 0.170 |
Why?
|
| Time Factors | 7 | 2021 | 6204 | 0.160 |
Why?
|
| Repressor Proteins | 1 | 2024 | 810 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2010 | 37 | 0.160 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2024 | 387 | 0.160 |
Why?
|
| Interleukin-18 | 2 | 2023 | 60 | 0.150 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2018 | 25 | 0.150 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2017 | 10 | 0.150 |
Why?
|
| Protein Precursors | 2 | 2021 | 149 | 0.150 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 5046 | 0.150 |
Why?
|
| Adipokines | 1 | 2018 | 58 | 0.150 |
Why?
|
| Risk | 5 | 2018 | 749 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 499 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2019 | 338 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 2585 | 0.140 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2014 | 83 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 352 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 766 | 0.140 |
Why?
|
| Interleukin-6 | 4 | 2024 | 393 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 171 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2021 | 765 | 0.130 |
Why?
|
| Life Style | 1 | 2018 | 402 | 0.130 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 31 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 2047 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 222 | 0.130 |
Why?
|
| White Matter | 1 | 2017 | 181 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1432 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 253 | 0.120 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 27 | 0.120 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 481 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 233 | 0.120 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2014 | 40 | 0.120 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 3379 | 0.120 |
Why?
|
| Subtilisins | 1 | 2014 | 10 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 76 | 0.120 |
Why?
|
| Cognition | 1 | 2019 | 735 | 0.110 |
Why?
|
| Athletes | 1 | 2014 | 61 | 0.110 |
Why?
|
| Particle Size | 1 | 2014 | 116 | 0.110 |
Why?
|
| Prevalence | 3 | 2017 | 2405 | 0.110 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 151 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2014 | 140 | 0.110 |
Why?
|
| Exome | 1 | 2018 | 1041 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 557 | 0.110 |
Why?
|
| Brain Infarction | 1 | 2013 | 30 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2016 | 815 | 0.110 |
Why?
|
| Brain | 3 | 2024 | 2946 | 0.110 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 54 | 0.100 |
Why?
|
| Calcinosis | 2 | 2014 | 168 | 0.100 |
Why?
|
| Adult | 9 | 2022 | 29032 | 0.100 |
Why?
|
| Dyslipidemias | 1 | 2015 | 228 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2016 | 528 | 0.100 |
Why?
|
| Phospholipases A2 | 3 | 2006 | 35 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 675 | 0.100 |
Why?
|
| Logistic Models | 2 | 2014 | 1796 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 337 | 0.100 |
Why?
|
| Apolipoprotein B-100 | 2 | 2001 | 33 | 0.100 |
Why?
|
| Apolipoproteins A | 2 | 2001 | 46 | 0.100 |
Why?
|
| Weight Loss | 3 | 2011 | 478 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 226 | 0.090 |
Why?
|
| Sex Factors | 4 | 2017 | 1255 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 2836 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2014 | 1541 | 0.090 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 2024 | 0.090 |
Why?
|
| Nursing Evaluation Research | 1 | 2010 | 7 | 0.090 |
Why?
|
| Dehydroepiandrosterone | 1 | 2010 | 16 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 55 | 0.090 |
Why?
|
| Alleles | 1 | 2015 | 1604 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2019 | 867 | 0.090 |
Why?
|
| Adipose Tissue | 2 | 2011 | 465 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 41 | 0.090 |
Why?
|
| Prolactin | 1 | 2010 | 103 | 0.090 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 67 | 0.090 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 63 | 0.090 |
Why?
|
| Body Weight | 1 | 2014 | 999 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 73 | 0.090 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 119 | 0.090 |
Why?
|
| Hydrocortisone | 1 | 2010 | 214 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2014 | 554 | 0.080 |
Why?
|
| Immunoassay | 3 | 2005 | 127 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 425 | 0.080 |
Why?
|
| Myocardial Revascularization | 1 | 2009 | 96 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2010 | 133 | 0.080 |
Why?
|
| Women's Health | 1 | 2010 | 130 | 0.080 |
Why?
|
| Postmenopause | 2 | 2020 | 124 | 0.080 |
Why?
|
| Dementia | 1 | 2014 | 448 | 0.080 |
Why?
|
| Age Factors | 4 | 2018 | 2799 | 0.080 |
Why?
|
| Liver | 2 | 2011 | 1734 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 3083 | 0.080 |
Why?
|
| Echocardiography | 2 | 2024 | 1059 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1011 | 0.080 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 27 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 429 | 0.070 |
Why?
|
| Phenotype | 2 | 2014 | 4221 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3526 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2014 | 1480 | 0.070 |
Why?
|
| Cytokines | 2 | 2010 | 1283 | 0.070 |
Why?
|
| Health Promotion | 1 | 2010 | 390 | 0.070 |
Why?
|
| Comorbidity | 3 | 2017 | 1497 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2014 | 1243 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1641 | 0.070 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2006 | 136 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 715 | 0.060 |
Why?
|
| Cystatin C | 2 | 2016 | 49 | 0.060 |
Why?
|
| Leptin | 3 | 2018 | 211 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 238 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2001 | 312 | 0.060 |
Why?
|
| Caveolins | 1 | 2003 | 15 | 0.060 |
Why?
|
| United Kingdom | 1 | 2024 | 191 | 0.060 |
Why?
|
| Azetidines | 2 | 2013 | 55 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 138 | 0.050 |
Why?
|
| Simvastatin | 2 | 2013 | 75 | 0.050 |
Why?
|
| Ezetimibe | 2 | 2013 | 95 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 624 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 129 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 281 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 206 | 0.050 |
Why?
|
| Adiponectin | 2 | 2018 | 109 | 0.050 |
Why?
|
| tau Proteins | 1 | 2024 | 189 | 0.050 |
Why?
|
| Lipoproteins, VLDL | 1 | 2001 | 58 | 0.050 |
Why?
|
| Mutation | 1 | 2015 | 5773 | 0.050 |
Why?
|
| Energy Intake | 1 | 2004 | 487 | 0.050 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 47 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2006 | 796 | 0.050 |
Why?
|
| India | 1 | 2001 | 217 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2001 | 251 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1312 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 174 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 409 | 0.040 |
Why?
|
| Smoking | 2 | 2016 | 1031 | 0.040 |
Why?
|
| Insulin | 3 | 2014 | 1197 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 43 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 1038 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 5 | 0.040 |
Why?
|
| Memory, Episodic | 1 | 2017 | 25 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 43 | 0.040 |
Why?
|
| Factor VIII | 1 | 2017 | 44 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 1069 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 142 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 247 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2017 | 150 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 459 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 72 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2017 | 197 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 239 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 586 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 921 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 271 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 1172 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 163 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 374 | 0.030 |
Why?
|
| Retirement | 1 | 2014 | 18 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 32 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 33 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1515 | 0.030 |
Why?
|
| Lipocalins | 1 | 2014 | 25 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 869 | 0.030 |
Why?
|
| Football | 1 | 2014 | 30 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2006 | 313 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 56 | 0.030 |
Why?
|
| Sitosterols | 1 | 2013 | 9 | 0.030 |
Why?
|
| Absorption | 1 | 2013 | 52 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 41 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 101 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 197 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1996 | 369 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 92 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 77 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 38 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 57 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 803 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1416 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 101 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 153 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1081 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2014 | 155 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2013 | 190 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 696 | 0.030 |
Why?
|
| Fasting | 1 | 2014 | 296 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 713 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2014 | 418 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 730 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 667 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 1993 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 259 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 48 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1387 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 79 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 42 | 0.020 |
Why?
|
| CD11c Antigen | 1 | 2011 | 35 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 204 | 0.020 |
Why?
|
| Caloric Restriction | 1 | 2011 | 84 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 17486 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1996 | 1019 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 374 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 515 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2005 | 15998 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 1743 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 759 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3047 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 176 | 0.020 |
Why?
|
| Diet, High-Fat | 1 | 2011 | 207 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1588 | 0.020 |
Why?
|
| Myocardium | 1 | 2014 | 982 | 0.020 |
Why?
|
| Calcium | 1 | 2014 | 1094 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4268 | 0.020 |
Why?
|
| Animals | 4 | 2019 | 33720 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 790 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 111 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2014 | 997 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 469 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2540 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 638 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 279 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2006 | 22 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 557 | 0.020 |
Why?
|
| Static Electricity | 1 | 2006 | 40 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 4345 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 444 | 0.020 |
Why?
|
| Microspheres | 1 | 2005 | 70 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2005 | 208 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 260 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2004 | 90 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2003 | 46 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 88 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 106 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 696 | 0.010 |
Why?
|
| Aminocaproic Acid | 1 | 2001 | 4 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 2001 | 20 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 370 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2001 | 96 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2001 | 29 | 0.010 |
Why?
|
| Tranexamic Acid | 1 | 2001 | 19 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 185 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 392 | 0.010 |
Why?
|
| Proline | 1 | 2001 | 73 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 1101 | 0.010 |
Why?
|
| Lysine | 1 | 2001 | 200 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2001 | 100 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 8865 | 0.010 |
Why?
|
| Arginine | 1 | 2001 | 298 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1390 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1682 | 0.010 |
Why?
|
| Texas | 1 | 2008 | 3547 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2774 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 12116 | 0.010 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 1996 | 37 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 19095 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 410 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 382 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 463 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 559 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 893 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 3093 | 0.010 |
Why?
|
| Gene Expression | 1 | 1996 | 1569 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 3871 | 0.010 |
Why?
|